{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:31:39Z","timestamp":1789421499213,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00277-011-1233-0","type":"journal-article","created":{"date-parts":[[2011,4,21]],"date-time":"2011-04-21T15:00:59Z","timestamp":1303398059000},"page":"103-107","source":"Crossref","is-referenced-by-count":11,"title":["Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg"],"prefix":"10.1007","volume":"91","author":[{"given":"Mandy N.","family":"Lauw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W. N.","family":"Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F. Y.","family":"van Wulfften Palthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa H.","family":"Homburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ellen","family":"van der Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"Koene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Biemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"issue":"4","key":"1233_CR1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33(4):313\u2013320","journal-title":"Semin Thromb Hemost"},{"issue":"9464","key":"1233_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061","journal-title":"Lancet"},{"issue":"7037","key":"1233_CR3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144\u20131148","journal-title":"Nature"},{"issue":"17","key":"1233_CR4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790","journal-title":"N Engl J Med"},{"key":"1233_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322","journal-title":"Leukemia"},{"issue":"11","key":"1233_CR6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3324\/haematol.13081","volume":"93","author":"F Girodon","year":"2008","unstructured":"Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD et al (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 93(11):1723\u20131727","journal-title":"Haematologica"},{"issue":"3","key":"1233_CR7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","volume":"109","author":"N Kroger","year":"2007","unstructured":"Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109(3):1316\u20131321","journal-title":"Blood"},{"issue":"8","key":"1233_CR8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4161\/cc.4.8.1872","volume":"4","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Gilliland DG (2005) JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 4(8):1053\u20131056","journal-title":"Cell Cycle"},{"issue":"9","key":"1233_CR9","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","volume":"20","author":"P Sidon","year":"2006","unstructured":"Sidon P, El Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9):1622","journal-title":"Leukemia"},{"issue":"3","key":"1233_CR10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","volume":"96","author":"C Nielsen","year":"2011","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450\u2013453","journal-title":"Haematologica"},{"issue":"1","key":"1233_CR11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","volume":"109","author":"X Xu","year":"2007","unstructured":"Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB et al (2007) JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 109(1):339\u2013342","journal-title":"Blood"},{"issue":"7","key":"1233_CR12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","volume":"130","author":"RK Patel","year":"2006","unstructured":"Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M et al (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130(7):2031\u20132038","journal-title":"Gastroenterology"},{"issue":"12","key":"1233_CR13","first-page":"1712","volume":"91","author":"JH Smalberg","year":"2006","unstructured":"Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW (2006) Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 91(12):1712\u20131713","journal-title":"Haematologica"},{"issue":"10","key":"1233_CR14","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S et al (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922\u20134929","journal-title":"Blood"},{"issue":"1","key":"1233_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","volume":"5","author":"D Colaizzo","year":"2007","unstructured":"Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA et al (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5(1):55\u201361","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1233_CR16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","volume":"5","author":"V Stefano De","year":"2007","unstructured":"De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P et al (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5(4):708\u2013714","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1233_CR17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","volume":"5","author":"S Regina","year":"2007","unstructured":"Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5(4):859\u2013861","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1233_CR18","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.leu.2404710","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Schwager S, Finke C, Hussein K, Pruthi RK et al (2007) JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 21(8):1828\u20131829","journal-title":"Leukemia"},{"issue":"4","key":"1233_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","volume":"83","author":"A Pardanani","year":"2008","unstructured":"Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK et al (2008) JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 83(4):457\u2013459","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1233_CR20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.10358","volume":"92","author":"AF Remacha","year":"2007","unstructured":"Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C et al (2007) The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 92(2):285\u2013286","journal-title":"Haematologica"},{"issue":"1","key":"1233_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1538-7836.2007.02811.x","volume":"6","author":"V Ugo","year":"2008","unstructured":"Ugo V, Le GG, Lecucq L, Mottier D, Oger E (2008) Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost 6(1):203\u2013205","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1233_CR22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1365-2141.2008.07537.x","volume":"144","author":"T Za","year":"2009","unstructured":"Za T, Fiorini A, Rossi E, Ciminello A, Chiusolo P, Leone G et al (2009) Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. Br J Haematol 144(6):965\u2013967","journal-title":"Br J Haematol"},{"issue":"9094","key":"1233_CR23","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(97)08140-3","volume":"350","author":"PS Wells","year":"1997","unstructured":"Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L et al (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350(9094):1795\u20131798","journal-title":"Lancet"},{"issue":"3","key":"1233_CR24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","volume":"20","author":"H Quentmeier","year":"2006","unstructured":"Quentmeier H, MacLeod RA, Zaborski M, Drexler HG (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20(3):471\u2013476","journal-title":"Leukemia"},{"issue":"1","key":"1233_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","volume":"94","author":"E Lippert","year":"2009","unstructured":"Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B et al (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94(1):38\u201345","journal-title":"Haematologica"},{"issue":"22","key":"1233_CR26","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","volume":"113","author":"F Dentali","year":"2009","unstructured":"Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M et al (2009) JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617\u20135623","journal-title":"Blood"},{"issue":"9","key":"1233_CR27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00277-008-0512-x","volume":"87","author":"I Rapado","year":"2008","unstructured":"Rapado I, Albizua E, Ayala R, Hernandez JA, Garcia-Alonso L, Grande S et al (2008) Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol 87(9):741\u2013749","journal-title":"Ann Hematol"},{"issue":"4","key":"1233_CR28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.21627","volume":"85","author":"C Martinaud","year":"2010","unstructured":"Martinaud C, Brisou P, Mozziconacci MJ (2010) Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 85(4):287\u2013288","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1233-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T23:04:05Z","timestamp":1497913445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1233-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1233-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,12]]}}}